GSK (NYSE: GSK) files 2025 Form 20-F with audited 2025 financial statements

Rhea-AI Filing Summary

GSK plc has filed its 2025 Annual Report on Form 20-F with the US Securities and Exchange Commission, providing audited financial statements for the year ended 31 December 2025.

The report is available online on both GSK’s annual report website and the SEC’s website. A hard copy of the 2025 Annual Report and the Notice of Annual General Meeting is expected to be available on or about 25 March 2026, and shareholders can request free hard copies of the complete audited financial statements from GSK’s UK registrar or its US ADR depositary.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Issued: 6 March 2026, London UK

GSK plc 2025 Annual Report on Form 20-F

In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, GSK plc ("GSK") announces that on 6 March 2026 it filed with the Securities and Exchange Commission an Annual Report on Form 20-F that included audited financial statements for the year ended 31 December 2025. GSK's 2025 Annual Report on Form 20-F is available online at GSK's website at: https://annualreport.gsk.com and also online at www.sec.gov.

A hard copy version of the GSK 2025 Annual Report, together with the Notice of Annual General Meeting, will be available on or about 25 March 2026.

Shareholders have the ability to receive, upon request, a hard copy version of GSK's complete audited financial statements for the year ended 31 December 2025, free of charge, by either:

(i)	writing to Computershare Investor Services, our registrars in the UK, at the following address: Computershare Investor Services, The Pavilions, Bridgwater Road, Bristol BS99 6ZY, United Kingdom, or by telephone on +44 (0) 370 707 1595 (please use the country code if calling from outside the UK); or
(ii)	writing to J.P. Morgan Chase Bank, N.A. our ADR depositary in the US, at the following address: Computershare Trust Company N.A., PO Box 43304, Providence, RI 02940-3304, or by telephone on +1 877 353 1154 or +1 781 575 4992 (outside the US).

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

Victoria Whyte

Company Secretary

6 March 2026

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk factors" in GSK's Annual Report on Form 20-F for 2025.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: March 06, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc

FAQ

What does GSK (GSK) announce in this Form 6-K filing?

GSK announces that it has filed its 2025 Annual Report on Form 20-F with the SEC. This report includes audited financial statements for the year ended 31 December 2025 and is available online via GSK’s annual report site and the SEC’s website.

Where can investors access GSK’s 2025 Form 20-F and audited financials?

Investors can access GSK’s 2025 Annual Report on Form 20-F at https://annualreport.gsk.com and at www.sec.gov. These sources provide the company’s audited financial statements for the year ended 31 December 2025 in electronic format.

How can GSK shareholders request a hard copy of the 2025 audited financial statements?

Shareholders can request a free hard copy of GSK’s complete audited financial statements for 2025 by writing to Computershare Investor Services in the UK or Computershare Trust Company N.A. in the US, or by calling the listed telephone numbers for each registrar.

When will GSK’s 2025 Annual Report hard copy and AGM Notice be available?

A hard copy of GSK’s 2025 Annual Report, together with the Notice of Annual General Meeting, will be available on or about 25 March 2026. This provides shareholders with physical documentation ahead of the company’s annual general meeting.

What period do GSK’s newly filed audited financial statements cover?

The audited financial statements included in GSK’s 2025 Annual Report on Form 20-F cover the year ended 31 December 2025. This annual period summarises the company’s consolidated financial performance and position as presented to US and international investors.

What caution does GSK give about forward-looking statements in this announcement?

GSK cautions that any forward-looking statements in the announcement are subject to risks and uncertainties. It refers readers to the “Risk factors” section under Item 3.D of its 2025 Form 20-F, where key risks that could affect actual results are described.